Role of surgical resection for non-colorectal non-neuroendocrine liver metastases

Table 6 Summary of studies with ≥ 40 patients who underwent hepatectomy for liver metastasis from breast cancer

Ref.	Year	Period	No. of patients	MST (mo)	3-ysr (%)	5-ysr (%)	MDFS (mo)	Factors associated with worse overall survival
Pocard et al[36]	2000	1988-1997	52	42	49	NR	NR	Disesase free interval ≤ 48 mo (univariate)
Elias et al[37]	2003	1986-2000	54	34	50	34	NR	Hormone receptor-negative
Adam et al[38]	2006	1984-2004	85	32	NR	37	20	Poor response to preoperative chemotherapy, R2, no repeat hepatectomy
Adam et al[10]1	2006	1983-2004	454	45	NR	41	NR	NR
Hoffman et al[39]	2010	1999-2008	41	58	68	48	34	Positive resection margin, disease-free interval < 24 mo
Abbott et al[40]	2012	1997-2010	86	57	NR	44	14	ER-negative, disease progression before hepatectomy
Groeschl et al[13]1	2012	1990-2009	115	52	52	27	22	NR
Mariani et al[41]	2013	1988-2007	51	91	NR	NR	NR	Non-hepatectomy3, bone metastasis4
Hoffmann et al[15]1	2015	2001-2012	42	63	NR	53	NR	NR
Sadot et al[42]	2016	1991-2014	692	502	NR	382	29	Lymph node metastasis in the primary tumor, absence of trastuzumab therapy, multiple liver metastases

¹As a part of the report of on-colorectal non-neuroendocrine liver metastases;

²Including 18 patients who underwent percutaneous ablation therapy;

³Comparison to the non-operation group;

⁴Comparison including patients without hepatectomy. MST: Median survival time; ysr: Year survival rate; NR: Not reported.